Development and validation of an eating behavior patient‐reported outcome measure in people living with obesity or overweight.
- Published in:
- Obesity (19307381), 2025, v. 33, n. 7, p. 1249, doi. 10.1002/oby.24299
- By:
- Publication type:
- Article
Works by Steen, Oren
Results: 4
1
2
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP‐1 receptor dual agonist.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 4, p. 1773, doi. 10.1111/dom.16167
- By:
- Publication type:
- Article
3
Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 993, doi. 10.1111/dom.16052
- By:
- Publication type:
- Article
4
Goal achievement of HbA1c and LDL‐cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL‐RCT.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 10, p. 1722, doi. 10.1111/dom.14084
- By:
- Publication type:
- Article